Journal
TRENDS IN CANCER
Volume 4, Issue 11, Pages 769-783Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2018.09.003
Keywords
-
Categories
Funding
- US National Institutes of Health (NIH) [R01-CA155693]
- Department of Defense [W81XWH-14-1-0575, W81XWH-16-1-0575]
- Chinese Ministry of Science and Technology (MOST) [2016YFA0101203]
- NIH [R21CA218635]
- Roswell Park Comprehensive Cancer Center
- National Cancer Institute (NCI) [P30CA016056]
Ask authors/readers for more resources
Prostate cancer (PCa) has a predominantly luminal phenotype. Basal cells were previously identified as a cell of origin for PCa, but increasing evidence implicates luminal cells as a preferred cell of origin for PCa, as well as key drivers of tumor development and progression. Prostate luminal cells are understudied compared with basal cells. In this review, we describe the contribution of prostate luminal progenitor (LP) cells to luminal cell development and their role in prostate development, androgen-mediated regeneration of castrated prostate, and tumorigenesis. We also discuss the potential value of LP transcriptomics to identify new targets and therapies to treat aggressive PCa. Finally, we propose future research directions focusing on molecular mechanisms underlying LP cell biology and heterogeneity in normal and diseased prostate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available